At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SKYE Skye Bioscience Inc.
Post-Market Trading 11-29 14:38:50 EST
4.49
+0.23
+5.40%
盘后4.38
-0.11-2.45%
13:49 EST
High4.59
Low4.22
Vol44.03K
Open4.35
D1 Closing4.26
Amplitude8.57%
Mkt Cap136.22M
Tradable Cap67.96M
Total Shares30.34M
T/O194.52K
T/O Rate0.29%
Tradable Shares15.14M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.